Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What is the right dose? The elusive optimal biologic dose in phase I clinical trials.

× No keyword cloud information.

28 in total

Review 1. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors: Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal: Target Oncol Date: 2010-04-02 Impact factor: 4.493

Review 2. Envisioning the future of early anticancer drug development.

Authors: Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal: Nat Rev Cancer Date: 2010-06-10 Impact factor: 60.716

Review 3. Translational research in phase I trials.

Authors: Angelica Fasolo; Cristiana Sessa
Journal: Clin Transl Oncol Date: 2009-09 Impact factor: 3.405

Review 4. A pharmacologic perspective on newly emerging T-cell manipulation technologies.

Authors: Dominic Smethurst
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

Review 5. Determining the optimal dose in the development of anticancer agents.

Authors: Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal: Nat Rev Clin Oncol Date: 2014-03-25 Impact factor: 66.675

6. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

Authors: Jian-Feng Lu; Erik Rasmussen; Beth Y Karlan; Ignace B Vergote; Lynn Navale; Mita Kuchimanchi; Rebeca Melara; Daniel E Stepan; David M Weinreich; Yu-Nien Sun
Journal: Cancer Chemother Pharmacol Date: 2012-01-01 Impact factor: 3.333

Review 7. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors: Mariell Pettersson; Craig M Crews
Journal: Drug Discov Today Technol Date: 2019-02-13

Review 8. Induced protein degradation: an emerging drug discovery paradigm.

Authors: Ashton C Lai; Craig M Crews
Journal: Nat Rev Drug Discov Date: 2016-11-25 Impact factor: 84.694

Review 9. The inverted pyramid of biomarker-driven trials.

Authors: Ignacio Garrido-Laguna; Manuel Hidalgo; Razelle Kurzrock
Journal: Nat Rev Clin Oncol Date: 2011-08-02 Impact factor: 66.675

10. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.

Authors: Armin Ghobadi; Jaebok Choi; Mark A Fiala; Theresa Fletcher; Jingxia Liu; Linda G Eissenberg; Camille Abboud; Amanda Cashen; Ravi Vij; Mark A Schroeder; Iskra Pusic; Keith Stockerl-Goldstein; Meagan Jacoby; Geoffrey Uy; John DiPersio; Peter Westervelt
Journal: Leuk Res Date: 2016-07-22 Impact factor: 3.156